Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,399 Million (Mid Cap)
42.00
NA
1.69%
-0.10
10.17%
4.13
Revenue and Profits:
Net Sales:
171 Million
(Quarterly Results - Mar 2026)
Net Profit:
37 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
41.14%
0%
41.14%
6 Months
75.23%
0%
75.23%
1 Year
35.37%
0%
35.37%
2 Years
34.33%
0%
34.33%
3 Years
-29.43%
0%
-29.43%
4 Years
-63.82%
0%
-63.82%
5 Years
-74.79%
0%
-74.79%
Shanghai Aladdin Biochemical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.86%
EBIT Growth (5y)
11.73%
EBIT to Interest (avg)
81.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.33
Tax Ratio
9.80%
Dividend Payout Ratio
55.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.10%
ROE (avg)
9.56%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
4.12
EV to EBIT
34.19
EV to EBITDA
26.60
EV to Capital Employed
3.92
EV to Sales
7.70
PEG Ratio
NA
Dividend Yield
1.19%
ROCE (Latest)
11.47%
ROE (Latest)
9.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
170.70
130.20
31.11%
Operating Profit (PBDIT) excl Other Income
45.40
43.70
3.89%
Interest
5.30
1.30
307.69%
Exceptional Items
-0.00
-0.20
100.00%
Consolidate Net Profit
37.30
29.60
26.01%
Operating Profit Margin (Excl OI)
265.70%
263.20%
0.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 31.11% vs 32.18% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 26.01% vs 73.10% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
690.40
529.70
30.34%
Operating Profit (PBDIT) excl Other Income
214.80
170.30
26.13%
Interest
28.20
8.40
235.71%
Exceptional Items
-2.90
0.40
-825.00%
Consolidate Net Profit
135.10
115.70
16.77%
Operating Profit Margin (Excl OI)
250.00%
242.20%
0.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 30.34% vs 31.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 16.77% vs 34.85% in Dec 2024
About Shanghai Aladdin Biochemical Technology Co., Ltd. 
Shanghai Aladdin Biochemical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






